The current organization of the eNose Company was founded in 2013. The eNose Company is mainly focused on exhaled breath analysis of patiënts for disease screening. After a number of pilot- studies in oncology, infectional- and neurological diseases, the eNose Company is fully focused on certain indications like Lung Cancer, Colon Cancer, Barrett's E., Lung embolism, Multiple Sclerose and Tuberculosis. Recently, we validated Lung Cancer by a multicenter validation study, and it will be the first indication with full clinical evidence based on the thesis of Lung physician Dr. S.Kort: "detection of lung cancer in exhaled breath with electronic nose technology"